Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon‐occluded transcatheter arterial chemoembolization: A retrospective cohort study

Abstract

Balloon-occluded transcatheter arterial chemoembolization may exert a good antitumor effect and result in good overall survival in select hepatocellular carcinoma patients.

Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision‐tree analysis after propensity score matching

“…Transcatheter arterial chemoembolization (TACE) is a standard therapy for unresectable HCC, especially for patients with BCLC B . Several studies have shown that TACE significantly improves patient survival compared to the best supportive care and can prolong survival in patients with multiple HCC tumors and no macrovascular invasion . However, long‐term prognosis of patients treated with TACE alone is unsatisfactory and overall survival at 3 years remains low (<30%) for intermediate HCC patients because of poor local control of HCC.…”

“…8 Several studies have shown that TACE significantly improves patient survival compared to the best supportive care and can prolong survival in patients with multiple HCC tumors and no macrovascular invasion. [9][10][11][12] However, long-term prognosis of patients treated with TACE alone is unsatisfactory 13 and overall survival at 3 years remains low (<30%) for intermediate HCC patients because of poor local control of HCC. Radiofrequency ablation (RFA) is the main treatment method for patients with inoperable and small HCCs.…”

Midterm Outcomes and Prognostic Factors of Patients Treated Using Microballoon-Occluded Transarterial Chemoembolization with Miriplatin: A Retrospective Study of 37 Cases

“…Consequently, B-TACE induced denser lipiodol emulsion accumulation and a good local control effect in the HCC nodules [11,17]. Recent studies reported favorable predictors affecting the local control effect after B-TACE as follows: portal vein visualization during B-TACE, tumor on the subcapsular portion, successful subsegmental feeding artery embolization [23], single HCC, AFP level < 20 ng/ml [18], high CT value immediately after B-TACE [24], and enhanced tumor stain on CT during hepatic angiography under balloon occlusion [25]. In the present study, balloon increase, absence of PVTT, absence of previous C-TACE, and maximum tumor size smaller than 2 cm were significantly associated with progression-free survival on the univariate analysis, but none were significantly associated with progression-free survival on the multivariate analysis.…”

“…Irie et al reported that the median survival time was 3.5 years in the 28 patients with 1 or 2 HCC nodules treated using B-TACE with doxorubicin hydrochloride and mitomycin C [26]. Hatanaka et al reported that the median survival time was 902 days in 66 patients treated using B-TACE with miriplatin [18]. In the present study, the 1-, 2-, and 3-year survival rates were 89.2%, 67.3%, and 60.9%, respectively.…”

“…Recently, some studies reported that relatively good local control could be obtained after B-TACE with miriplatin without a significant increase in adverse effects than that after conventional-TACE (C-TACE) using miriplatin [16,17]. To the best of our knowledge, only one previous report has documented the survival rate following B-TACE with miriplatin [18]. The aim of this retrospective study was to analyze patients' midterm survival after B-TACE with miriplatin for HCCs and to identify the prognostic factors.…”